Immunome Inc Ordinary Shares IMNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Trading Information
- Previous Close Price
- $18.70
- Day Range
- $18.19–18.92
- 52-Week Range
- $16.13–30.05
- Bid/Ask
- $18.44 / $18.52
- Shares Outstanding
- 118.07M
- Market Cap
- $2.18B
- Volume/Avg
- 250,702 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 177
- Website
- https://www.immunome.com
Valuation
Metric | IMNM |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.68 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | IMNM |
|---|---|
Quick Ratio | 11.27 |
Current Ratio | 11.66 |
Interest Coverage | — |
Quick Ratio
IMNM
Profitability
Metric | IMNM |
|---|---|
Return on Assets (Normalized) | −45.84% |
Return on Equity (Normalized) | −49.69% |
Return on Invested Capital (Normalized) | −52.76% |
Return on Assets
IMNM
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%tgc%C | LOCK|y!f? | $138B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!?N#!c | LOCK|GwH# | $98B | |||
| Moderna Inc MRNA | LOCK|&f?TTC@ | LOCK|jPS | $94B | |||
| argenx SE ADR ARGX | LOCK|ys$!%!^ | LOCK|!nh | $62B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|fPLx<R | LOCK|>? | $50B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|@Vh>#@G | LOCK|$%kz | $31B | |||
| Incyte Corp INCY | LOCK|#F>#p^ | LOCK|>M | $25B | |||
| BioNTech SE ADR BNTX | LOCK|<s<S!g> | LOCK|><V | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|www#Db | LOCK|D#ZqX | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|k!!fHb | LOCK|S# | $15B |
United States